KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$1.87.

  • Nektar Therapeutics' EPS (Basic) rose 2969.92% to -$1.87 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.63, marking a year-over-year increase of 15314.79%. This contributed to the annual value of -$0.58 for FY2024, which is 6009.91% up from last year.
  • Per Nektar Therapeutics' latest filing, its EPS (Basic) stood at -$1.87 for Q3 2025, which was up 2969.92% from -$2.95 recorded in Q2 2025.
  • Nektar Therapeutics' 5-year EPS (Basic) high stood at $0.04 for Q4 2024, and its period low was -$3.76 during Q2 2024.
  • For the 5-year period, Nektar Therapeutics' EPS (Basic) averaged around -$0.94, with its median value being -$0.68 (2021).
  • Data for Nektar Therapeutics' EPS (Basic) shows a peak YoY increase of 11598.84% (in 2024) and a maximum YoY decrease of 129259.26% (in 2024) over the last 5 years.
  • Quarter analysis of 5 years shows Nektar Therapeutics' EPS (Basic) stood at -$0.8 in 2021, then soared by 60.07% to -$0.32 in 2022, then skyrocketed by 31.25% to -$0.22 in 2023, then surged by 115.99% to $0.04 in 2024, then crashed by 5416.37% to -$1.87 in 2025.
  • Its last three reported values are -$1.87 in Q3 2025, -$2.95 for Q2 2025, and -$0.24 during Q1 2025.